Xi Venture Capital was awarded the "Best Investment Institution for Innovative Medicine of the Year"

　　On April 26th, Haoyue Capital released the "2024 8th Medical and Health Investment Zhuoyue List". Xicheng Venture Capital was awarded the "Best Innovative Pharmaceutical Investment Institution of the Year" and "Best Early Investment Institution of the Medical and Health Industry of the Year" for its outstanding performance in the biopharmaceutical investment field in 2023. At the same time, Fu Haiying, the Managing Director of the company's biopharmaceutical team, was honored with the "Young Investor of the Medical and Health Industry of the Year".

Since its establishment, the biopharmaceutical team of Xi Venture Capital has relied on the local industrial advantages of Wuxi, adhered to the path of marketization and specialization, and established a top-down investment research system. Xi Venture Capital has invested in more than 10 industry-leading companies in the fields of innovative drugs and medical devices, such as Xiantong Pharmaceutical and Ruiyue Medical. At the same time, it provides better services to the invested enterprises through resource and industry empowerment. In 2023, it has won multiple equity investment industry honors such as the "Top 20 China Medical and Health Industry Investment Funds" and the "2023 Performance Contribution Award" with a total of 36 RMB. Future Xi Venture Capital will continue to forge ahead and explore and invest in more valuable enterprises.